Risperdal Jury Orders J&J to Pay $2.5 Billion in Gynecomastia Case
Johnson & Johnson has been ordered to pay $2.5 million to the family of an autistic man whose Risperdal lawsuit alleged complications associated with gynecomastia, a condition referring to male breast growth, Philly.com reports.
A verdict was reached February 24th in the Philadelphia Court of Common Pleas after jurors ruled in favor of the plaintiff, whose injuries resulted from his use of the antipsychotic medication as a child. This was the first product liability suit alleging gynecomastia complications to go to trial in the U.S., but will likely precede others now pending in states including California, Missouri and Pennsylvania, where a state docket is underway in Philadelphia. As of February 2015, more than 1,270 Risperdal lawsuits had been filed in this litigation on behalf of individuals who accuse Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, of concealing vital safety information about the medication from consumers.
Included as evidence heard in the recently concluded Risperdal trial was the testimony of a former commissioner for the U.S. Food and Drug Administration (FDA), who said the companies knew about problems with Risperdal since 2001, but failed to alert the agency about them. This and other information presented in the case made the juror’s decision an easy one, according to a Risperdal attorney for the plaintiff. “The jury in Philadelphia heard evidence that was never presented to the FDA by an American drug company. If there was ever a clear failure-to-warn case, this was it,” he said.
J&J Vows to Appeal Risperdal Verdict
In contrast, Johnson & Johnson and Janssen told Philly.com they were “disappointed” with the outcome of the case, and will consider an appeal to prove the safety and effectiveness of its product.
This is not the first time Johnson & Johnson has faced a large financial penalty related to Risperdal. In November 2013, the healthcare giant paid $2.5 billion to resolve claims involving Risperdal and several other medications that were filed by the U.S. Department of Justice. Among other things, the federal government accused Johnson & Johnson of promoting the medication off-label to treat elderly patients with dementia and certain pediatric uses that had not been cleared by the FDA. They also concealed information pertaining to Risperdal gynecomastia, according to claims.
Considering a Risperdal Lawsuit? Call Us.
Call a Risperdal lawyer today at (877) 779-1414 for more information about claims involving this medication. You may be entitled to compensation for substantial injury-related damages.